An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis, Dermatology, Dermatology, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any - 17 |
| Updated: | 12/9/2018 |
| Start Date: | August 2016 |
| End Date: | December 12, 2017 |
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Atopic Dermatitis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following
Treatment with DSXS in Patients with Atopic Dermatitis
Treatment with DSXS in Patients with Atopic Dermatitis
To evaluate the potential of DSXS topical product to suppress HPA axis function in patients
with moderate to severe atopic dermatitis.
with moderate to severe atopic dermatitis.
Inclusion Criteria:
- Parent/legal guardian has signed informed consent form, which meets all criteria of
current FDA regulations.
Exclusion Criteria:
- Females who are pregnant, nursing, planning to become pregnant during the duration of
the study, or if of child-bearing potential and sexually active and not prepared to
use appropriate contraceptive methods to avoid pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
